Davis TA - Search Results

1

Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.

Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Davis TA, et al. Blood. 1998 Aug 15;92(4):1184-90. Blood. 1998. PMID: 9694706 Free article. Clinical Trial.

2

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.

Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R. Timmerman JM, et al. Among authors: davis ta. Blood. 2002 Mar 1;99(5):1517-26. doi: 10.1182/blood.v99.5.1517. Blood. 2002. PMID: 11861263 Free article. Clinical Trial.

3

Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.

Davis TA, Hsu FJ, Caspar CB, van Beckhoven A, Czerwinsk DK, Liles TM, Taidi B, Benike CJ, Engleman EG, Levy R. Davis TA, et al. Biol Blood Marrow Transplant. 2001;7(9):517-22. doi: 10.1053/bbmt.2001.v7.pm11669219. Biol Blood Marrow Transplant. 2001. PMID: 11669219 Free article. Clinical Trial.

4

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. Maloney DG, et al. Blood. 1997 Sep 15;90(6):2188-95. Blood. 1997. PMID: 9310469 Free article. Clinical Trial.

5

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.

Davis TA, Czerwinski DK, Levy R. Davis TA, et al. Clin Cancer Res. 1999 Mar;5(3):611-5. Clin Cancer Res. 1999. PMID: 10100713

6

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.

Davis TA, White CA, Grillo-López AJ, Velásquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R. Davis TA, et al. J Clin Oncol. 1999 Jun;17(6):1851-7. doi: 10.1200/JCO.1999.17.6.1851. J Clin Oncol. 1999. PMID: 10561225 Clinical Trial.

7

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Davis TA, et al. J Clin Oncol. 2000 Sep;18(17):3135-43. doi: 10.1200/JCO.2000.18.17.3135. J Clin Oncol. 2000. PMID: 10963642 Clinical Trial.

8

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-López A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R. Knox SJ, et al. Clin Cancer Res. 1996 Mar;2(3):457-70. Clin Cancer Res. 1996. PMID: 9816191

9

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.

Davis TA, Maloney DG, Grillo-López AJ, White CA, Williams ME, Weiner GJ, Dowden S, Levy R. Davis TA, et al. Clin Cancer Res. 2000 Jul;6(7):2644-52. Clin Cancer Res. 2000. PMID: 10914705 Clinical Trial.

10

The radioisotope contributes significantly to the activity of radioimmunotherapy.

Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ. Davis TA, et al. Clin Cancer Res. 2004 Dec 1;10(23):7792-8. doi: 10.1158/1078-0432.CCR-04-0756. Clin Cancer Res. 2004. PMID: 15585610 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

427 results

Search Page

Filters